https://www.cochranelibrary.com/web/cochrane/content?templateType=full&urlTitle=/cdsr/doi/10.1002/14651858.CD015395.pub3&doi=10.1002/14651858.CD015395.pub3&type=cdsr&contentLanguage=&highlightAbstract=paxlovid
Lots of criticism levelled at Starpharma for not conducting human placebo trials. But in January we got a great significant human covid treatment trial. I think this report by Cochrane Org about Paxlovid changes perspective and one really questions how TGA meekly followed FDA and gave TA temporary approval to Pfizer. Cochrane seems very unimpressed
- Forums
- ASX - By Stock
- SPL
- If Viraleze 7 day treatment is competing with Paxlovid - who wins
If Viraleze 7 day treatment is competing with Paxlovid - who wins
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
|
|||||
Last
9.6¢ |
Change
0.001(1.05%) |
Mkt cap ! $39.58M |
Open | High | Low | Value | Volume |
9.5¢ | 9.6¢ | 9.4¢ | $36.11K | 379.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 46102 | 9.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.7¢ | 560 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 46102 | 0.096 |
1 | 175018 | 0.095 |
2 | 99598 | 0.094 |
1 | 100000 | 0.093 |
1 | 49413 | 0.091 |
Price($) | Vol. | No. |
---|---|---|
0.097 | 560 | 1 |
0.098 | 217576 | 1 |
0.099 | 71285 | 2 |
0.100 | 112106 | 4 |
0.105 | 66531 | 3 |
Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online